<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Metastasis</z:e> is the main cause of mortality in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, most of the targeted therapies and predictive molecular biomarkers were developed based mainly on <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The current study was conducted to determine the degree of discordance between potential predictive and/or prognostic molecular markers in primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> and corresponding <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, as this could have an impact on the efficacy of targeted therapies in the advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>KRAS, PIK3CA and BRAF mutations were determined by Sanger sequencing and mutant-enriched polymerase chain reaction (PCR) assays in 83 paired samples, MET gene copy number by quantitative PCR in 59, MET expression by immunohistochemistry in 73 and nuclear and cytoplasmic expression of PTEN by immunohistochemistry in 78 and 71 pairs, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>A certain degree of discordance between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and corresponding <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> was demonstrated for <z:hpo ids='HP_0000001'>all</z:hpo> examined biomarkers except BRAF mutations </plain></SENT>
<SENT sid="5" pm="."><plain>PIK3CA exon 9 mutations in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and loss of PTEN nuclear expression in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> correlated with KRAS mutations </plain></SENT>
<SENT sid="6" pm="."><plain>KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> status in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> was associated with loss of PTEN cytoplasmic expression and high gene copy number of MET </plain></SENT>
<SENT sid="7" pm="."><plain>Survival and clinical data were available for 68 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The multiple regression analysis revealed that the right-sided <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> localization and overexpression of MET were associated with shorter overall survival </plain></SENT>
</text></document>